Dimensional Fund Advisors LP Has $6.23 Million Stock Holdings in Cytokinetics, Incorporated $CYTK

Key Points

• Dimensional Fund Advisors increased its Cytokinetics stake by 75.2% in the first quarter, owning 94,503 shares valued at approximately $6.23 million. Several other institutional investors also raised their positions.
• Cytokinetics reported a quarterly loss of $1.50 per share, beating the $1.63 consensus estimate, while revenue of $28.62 million exceeded expectations. However, revenue declined 57.1% year over year.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $101.15 versus the stock’s recent price near $76.45. Company executives have continued selling shares under pre-arranged Rule 10b5-1 trading plans.

Dimensional Fund Advisors LP boosted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 75.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 94,503 shares of the biopharmaceutical company's stock after acquiring an additional 40,574 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.08% of Cytokinetics worth $6,229,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. AlphaCentric Advisors LLC raised its stake in Cytokinetics by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the biopharmaceutical company's stock valued at $370,000 after purchasing an additional 305 shares in the last quarter. Swiss National Bank raised its position in Cytokinetics by 2.5% during the 1st quarter. Swiss National Bank now owns 229,800 shares of the biopharmaceutical company's stock valued at $15,146,000 after purchasing an additional 5,600 shares during the last quarter. California Public Employees Retirement System raised its position in shares of Cytokinetics by 4.8% in the 1st quarter. California Public Employees Retirement System now owns 198,530 shares of the biopharmaceutical company's stock worth $13,085,000 after purchasing an additional 9,129 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Cytokinetics by 14.5% during the 1st quarter. Assetmark Inc. now owns 3,463 shares of the biopharmaceutical company's stock worth $228,000 after acquiring an additional 438 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Cytokinetics by 10.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 6,989 shares of the biopharmaceutical company's stock valued at $466,000 after purchasing an additional 646 shares in the last quarter.

Insider Activity at Cytokinetics

In other news, EVP Andrew Callos sold 14,000 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total transaction of $1,118,320.00. Following the transaction, the executive vice president directly owned 58,555 shares of the company's stock, valued at $4,677,373.40. This represents a 19.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Ibraham Malik sold 3,500 shares of the business's stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $80.59, for a total transaction of $282,065.00. Following the sale, the executive vice president directly owned 153,902 shares of the company's stock, valued at approximately $12,402,962.18. The trade was a 2.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 122,679 shares of company stock valued at $9,701,754 in the last quarter. 2.60% of the stock is currently owned by corporate insiders.

Cytokinetics Stock Performance

NASDAQ CYTK opened at $76.45 on Wednesday. Cytokinetics, Incorporated has a 52-week low of $33.17 and a 52-week high of $88.31. The company has a 50-day simple moving average of $79.10 and a 200 day simple moving average of $71.15. The company has a market capitalization of $9.51 billion, a PE ratio of -10.59 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to the consensus estimate of $17.59 million. During the same quarter in the prior year, the business posted ($1.12) EPS. The firm's revenue for the quarter was down 57.1% on a year-over-year basis. As a group, analysts forecast that Cytokinetics, Incorporated will post -6 EPS for the current fiscal year.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The analyst improved its Q3 2026 EPS estimate to $(1.65) from $(1.80), Q4 to $(1.55) from $(1.86), and full-year 2026 to $(6.38) from $(6.86). HC Wainwright also retained a $140 price target, well above recent trading levels, signaling confidence in Cytokinetics’ development pipeline and future prospects.
• Positive Sentiment: Other analysts have recently increased their price targets. Citizens JMP raised its target to $110, Truist Financial lifted its target to $112, and UBS upgraded the stock to Buy with a $115 target. The analyst consensus remains “Moderate Buy,” with an average target of approximately $101.15. Cytokinetics Price Target Raised to $110 Cytokinetics Price Target Raised to $112
• Neutral Sentiment: Reported short-interest data showed no measurable short position. The filing listed short interest at zero shares and a zero-day short-interest ratio, but the reported percentage change was unavailable. Consequently, the data provides little actionable information about potential short-covering or bearish positioning.
• Negative Sentiment: CEO Robert Blum sold 7,500 shares worth approximately $575,700. The transaction reduced his direct holdings by 1.95%, which can create a modest negative signal for investors. However, the sale was executed under a pre-arranged Rule 10b5-1 trading plan, making it less indicative of a discretionary bearish view. Insider Selling: Cytokinetics CEO Sells 7,500 Shares

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cytokinetics in a research report on Friday, July 17th. Stifel Nicolaus boosted their target price on shares of Cytokinetics from $98.00 to $108.00 and gave the stock a "buy" rating in a research report on Wednesday, May 6th. Needham & Company LLC raised their price objective on shares of Cytokinetics from $102.00 to $112.00 and gave the company a "buy" rating in a research note on Friday, August 7th. HC Wainwright upped their price target on Cytokinetics from $136.00 to $140.00 and gave the stock a "buy" rating in a research note on Monday, May 11th. Finally, Truist Financial increased their target price on shares of Cytokinetics from $106.00 to $112.00 and gave the stock a "buy" rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $101.15.

Cytokinetics Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source